Integrated Diagnostics Inc. (Indidx) has raised the bar on lung cancer detection with publication of study results regarding its Xpresys Lung 2 (XL2) liquid biopsy test for early stage disease. The differential diagnostic test has been confirmed to provide accurate distinction between benign and malignant nodules, possibly avoiding unnecessary biopsy or surgery in early suspect nodules. The study was published online Feb. 26, 2018, in CHEST, the journal of the American College of Chest Physicians.